Cambridge Investment Research Advisors’s Kindred Biosciences, Inc. KIN Stock Holding History

Cambridge Investment Research Advisors’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-64,746	Closed	-$322K	–	3195
2021 Q1	$322K	Buy	64,746 +1,500	+2%	+$7.25K	﹤0.01%	2232
2020 Q4	$273K	Hold	63,246	–	–	﹤0.01%	2227
2020 Q3	$271K	Sell	63,246 -200	-0.3%	-$836	﹤0.01%	2015
2020 Q2	$285K	Buy	63,446 +6,219	+11%	+$27.8K	﹤0.01%	1927
2020 Q1	$229K	Buy	57,227 +26,177	+84%	+$222K	﹤0.01%	1845
2019 Q4	$263K	Buy	+31,050	New	+$242K	﹤0.01%	1999

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Cambridge Investment Research Advisors's KIN Position: Q2 2021 in Review

Cambridge Investment Research Advisors sold out of Kindred Biosciences, Inc. (KIN) in Q2 2021, closing a stake of 64,746 shares — an estimated $322K sold.

Cambridge Investment Research Advisors first reported a position in KIN in Q4 2019 and held it in 6 quarters. The position peaked at $322K in Q1 2021. 87 funds tracked by Wall St. Rank hold KIN as of Q2 2021.

Cambridge Investment Research Advisors reported no remaining Kindred Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
Cambridge Investment Research Advisors sold 64,746 Kindred Biosciences, Inc. shares in Q2 2021, an estimated $322K.
Cambridge Investment Research Advisors first reported a position in Kindred Biosciences, Inc. in Q4 2019 and held it in 6 quarters.
Cambridge Investment Research Advisors's Kindred Biosciences, Inc. position peaked at $322K in Q1 2021.
87 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2021, filed 10 Aug 2021.